Related references
Note: Only part of the references are listed.Reducing Senescent Cell Burden in Aging and Disease
Robert J. Pignolo et al.
TRENDS IN MOLECULAR MEDICINE (2020)
Targeting senescent cells alleviates obesity-induced metabolic dysfunction
Allyson K. Palmer et al.
AGING CELL (2019)
Fisetin is a senotherapeutic that extends health and lifespan
Matthew J. Yousefzadeh et al.
EBIOMEDICINE (2018)
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Yi Zhu et al.
AGING CELL (2015)
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Allyson K. Palmer et al.
DIABETES (2015)
Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Athanasios Fountas et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2015)
Tyrosine Kinase Inhibitor Sunitinib Allows Insulin Independence in Long- standing Type 1 Diabetes
Mohammed S. B. Huda et al.
DIABETES CARE (2014)
Hyperglycemia causes cellular senescence via a SGLT2-and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy
Kento Kitada et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review
Massimo Breccia et al.
LEUKEMIA RESEARCH (2014)
Association Between Glycosylated Hemoglobin and Intentional Weight Loss in Overweight and Obese Patients With Type 2 Diabetes Mellitus A Retrospective Cohort Study
Ghanshyam Palamaner Subash Shantha et al.
DIABETES EDUCATOR (2012)
Rapid Amelioration of Hyperglycemia Facilitated by Dasatinib in a Chronic Myeloid Leukemia Patient with type 2 Diabetes Mellitus
Keiko Ono et al.
INTERNAL MEDICINE (2012)
Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia
Stefania Mariani et al.
LEUKEMIA RESEARCH (2010)
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
Nicole M Agostino et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
A crucial role for adipose tissue p53 in the regulation of insulin resistance
Tohru Minamino et al.
NATURE MEDICINE (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib
M. Breccia et al.
LEUKEMIA RESEARCH (2008)
Imatinib and regression of type 2 diabetes
D Veneri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Imatinib mesylate may improve fasting blood glucose in diabetic Ph plus chronic myelogenous leukemia patients responsive to treatment
M Breccia et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
